Leads Biolabs-B (09887) Presents Updated Clinical Data for LBL-034 in Relapsed/Refractory Multiple Myeloma at 2026 ESMO Congress

Stock News10-25

Leads Biolabs-B (09887) has announced that on October 24, 2026, updated results from the first-in-human clinical study of LBL-034 (a GPRC5D/CD3 bispecific T-cell engager, TCE) for the treatment of relapsed/refractory multiple myeloma (RRMM) were presented as an oral presentation at the 2026 European Society for Medical Oncology Congress (2026 ESMO).

LBL-034 achieved deep and durable responses in heavily pretreated, high-risk patients with relapsed/refractory multiple myeloma (RRMM), while demonstrating an excellent safety profile, namely a low and manageable incidence of cytokine release syndrome (CRS).

These data provide robust clinical validation of the efficacy and safety of the conditional T-cell redirection and priming mechanism that is unique to the company's LeadsBody™ TCE platform, and also lay a solid foundation for expanding the company's TCE pipeline from hematological malignancies to autoimmune diseases and solid tumors.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment